Healthcare-associated Staphylococcus aureus bacteremia in children: Evidence for reverse vancomycin creep and impact of vancomycin trough values on outcome

Pediatric Infectious Disease Journal

Volumn 35, Issue 3, 2016, Pages 263-268

  McNeil, J Chase ^a,b   Kok, Eric Y ^a,b   Forbes, Andrea R ^a,b   Lamberth, Linda ^a,b   Hulten, Kristina G ^a,b   Vallejo, Jesus G ^a,b   Mason, Edward O ^a,b   Kaplan, Sheldon L ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Bacteremia; Children; Creep; S. aureus; Vancomycin

Indexed keywords

CREATININE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ARTICLE; BACTERIUM ISOLATE; CHILD; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SURVEILLANCE; DRUG BLOOD LEVEL; EPSILOMETER TEST; FEMALE; HEALTHCARE ASSOCIATED INFECTION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MINIMUM INHIBITORY CONCENTRATION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; STAPHYLOCOCCAL BACTEREMIA; ANTIBIOTIC RESISTANCE; BACTEREMIA; CROSS INFECTION; DRUG EFFECTS; ISOLATION AND PURIFICATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PRESCHOOL CHILD; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEXAS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CHILD, PRESCHOOL; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEXAS; VANCOMYCIN;

EID: 84959198970     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000991     Document Type: Article

References (38)

1. Liu C, Bayer A, Cosgrove SE, et al; Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18-e55.
2. Kullar R, Davis SL, Levine DP, et al. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011;52:975-981.
3. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29:1275-1279.
4. Chhim RF, Arnold SR, Lee KR. Vancomycin dosing practices, trough concentrations, and predicted area under the curve in children with suspected invasive staphylococcal infections. J Pediatric Infect Dis Soc. 2013;2: 259-262.
5. Knoderer CA, Nichols KR, Lyon KC, et al. Are elevated vancomycin serum trough concentrations achieved within the first 7 days of therapy associated with acute kidney injury in children? J Pediatric Infect Dis Soc. 2014;3:127-131.
6. Frymoyer A, Guglielmo BJ, Hersh AL. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant staphylococcal infections. Pediatr Infect Dis J. 2013;32:1077-1079.
7. Wang G, Hindler JF, Ward KW, et al. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol. 2006;44:3883-3886.
8. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007;60:788-794.
9. Hawser SP, Bouchillon SK, Hoban DJ, et al. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009. Int J Antimicrob Agents. 2011;37:219-224.
10. Hsu DI, Hidayat LK, Quist R, et al. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents. 2008;32:378-385.
11. Miller CE, Batra R, Cooper BS, et al. An association between bacterial genotype combined with a high-vancomycin minimum inhibitory concentration and risk of endocarditis in methicillin-resistant Staphylococcus aureus bloodstream infection. Clin Infect Dis. 2012;54:591-600.
12. Mason EO, Lamberth LB, Hammerman WA, et al. Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005. J Clin Microbiol. 2009;47:1628-1630.
13. Goldman JL, Harrison CJ, Myers AL, et al. No evidence of vancomycin minimal inhibitory concentration creep or heteroresistance identified in pediatric Staphylococcus aureus blood isolates. Pediatr Infect Dis J. 2014;33:216-218.
14. Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis. 2005;40:1785-1791.
15. Hultén KG, Kaplan SL, Lamberth LB, et al. Hospital-acquired Staphylococcus aureus infections at Texas Children's Hospital, 2001-2007. Infect Control Hosp Epidemiol. 2010;31:183-190.
16. Hultén KG, Kaplan SL, Gonzalez BE, et al. Three-year surveillance of community onset health care-associated staphylococcus aureus infections in children. Pediatr Infect Dis J. 2006;25:349-353.
17. Carrillo-Marquez MA, Hulten KG, Mason EO, et al. Clinical and molecular epidemiology of Staphylococcus aureus catheter-related bacteremia in children. Pediatr Infect Dis J. 2010;29:410-414.
18. Edwards JR, Peterson KD, Andrus ML, et al; NHSN Facilities. National Healthcare Safety Network (NHSN) report, data summary for 2006, issued June 2007. Am J Infect Control. 2007;35:290-301.
19. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30: 633-638.
20. Moffett BS, Hilvers PS, Dinh K, et al. Vancomycin-associated acute kidney injury in pediatric cardiac intensive care patients. Congenit Heart Dis. 2015;10:E6-E10.
21. CLSI. Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement. In: Institute CLS, ed. CLSI Document M100-S20-U. Wayne, PA: CLSI; 2010.
22. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008;52:3315-3320.
23. Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis. 2011;204:340-347.
24. Hultén KG, Kaplan SL, Gonzalez BE, et al. Three-year surveillance of community onset health care-associated Staphylococcus aureus infections in children. Pediatr Infect Dis J. 2006;25:349-353.
25. Moore PC, Lindsay JA. Genetic variation among hospital isolates of methicillin-sensitive Staphylococcus aureus: evidence for horizontal transfer of virulence genes. J Clin Microbiol. 2001;39:2760-2767.
26. Viedma E, Sanz F, Orellana MA, et al. Relationship between agr dysfunction and reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus causing bacteraemia. J Antimicrob Chemother. 2014;69:51-58.
27. Holmes NE, Turnidge JD, Munckhof WJ, et al. Genetic and molecular predictors of high vancomycin MIC in Staphylococcus aureus bacteremia isolates. J Clin Microbiol. 2014;52:3384-3393.
28. McCaskill ML, Mason EO Jr, Kaplan SL, et al. Increase of the USA300 clone among community-acquired methicillin-susceptible Staphylococcus aureus causing invasive infections. Pediatr Infect Dis J. 2007;26:1122-1127.
29. Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46:193-200.
30. Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925-942.
31. Mohr JF, Murray BE. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2007;44:1536-1542.
32. Charles PG, Ward PB, Johnson PD, et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004;38:448-451.
33. Sinclair EA, Yenokyan G, McMunn A, et al. Factors associated with acute kidney injury in children receiving vancomycin. Ann Pharmacother. 2014;48:1555-1562.
34. Kim SH, Kim KH, Kim HB, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2008;52:192-197.
35. Lodise TP Jr, McKinnon PS, Levine DP, et al. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2007;51:3731-3733.
36. McConeghy KW, Bleasdale SC, Rodvold KA. The empirical combination of vancomycin and a β-lactam for staphylococcal bacteremia. Clin Infect Dis. 2013;57:1760-1765.
37. Totapally BR, Machado J, Lee H, et al. Acute kidney injury during vancomycin therapy in critically ill children. Pharmacotherapy. 2013;33:598-602.
38. Akcan-Arikan A, Zappitelli M, Loftis LL, et al. Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int. 2007;71:1028-1035.